Evidence map›Paper›PMID 40405704›Full record

ArticleTechnology in cancer research & treatment

Machine Learning Model Integrating CT Radiomics of the Lung to Predict Checkpoint Inhibitor Pneumonitis in Patients with Advanced Cancer.

François Cousin, Thomas Louis, Pierre Frères, Julien Guiot, Mariaelena Occhipinti, Fabio Bottari, Wim Vos, Roland Hustinx

Abstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis 
of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

François CousinDepartment of Nuclear Medicine and Oncological Imaging, University Hospital (CHU) of Liège, Liège, Belgium.ORCID 0000-0003-4014-0297
Thomas LouisRadiomics (Oncoradiomics SA), Liège, Belgium.
Pierre FrèresDepartment of Medical Oncology, University Hospital (CHU) of Liège, Liège, Belgium.
Julien GuiotDepartment of Respiratory Medicine, University Hospital (CHU) of Liège, Liège, Belgium.
Mariaelena OcchipintiRadiomics (Oncoradiomics SA), Liège, Belgium.
Fabio BottariRadiomics (Oncoradiomics SA), Liège, Belgium.
Wim VosRadiomics (Oncoradiomics SA), Liège, Belgium.
Roland HustinxDepartment of Nuclear Medicine and Oncological Imaging, University Hospital (CHU) of Liège, Liège, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveCheckpoint inhibitor pneumonitis (CIP) is a potentially life-threatening immune-related adverse event. Efficient strategies to select patients at risk are still required. The aim of our study was to assess the utility of a machine learning model, integrating pre-treatment CT lung radiomics features with clinical data, to predict patients at risk of developing CIP.MethodsIn this retrospective study, 116 patients with varied malignancies treated with immune checkpoint inhibitors (ICIs) were included. In this cohort, 35 patients presented with CIP and 81 patients did not. Each lung and its lobes were segmented on pre-treatment CT scans to perform a handcrafted radiomic analysis. Radiomic features were associated with clinical parameters to build generalized linear (GLM) and random forest (RF) models, to predict occurrence of CIP. The models were fine-tuned, validated and tested using a nested 5-fold cross-validation method.ResultsThe RF models combining radiomic and clinical features showed the best performances with an area under the ROC curve (AUC) of 0.75 (95%CI:0.62-0.88) on the test set. The most accurate clinical model was a RF model and achieved an AUC of 0.72 (95%CI:0.51-0.92). The best radiomic model was a GLM model and achieved an AUC of 0.71 (95%CI:0.58-0.84).ConclusionsOur CT-based lung radiomic models showed moderate to good performance at predicting CIP. We demonstrated the potential role of machine learning models associating clinical parameters and lung CT radiomic features to better identify patients treated with ICIs at risk of developing CIP.Advances in knowledge: Radiomics analysis of the lung parenchyma could be used as a non-invasive tool to select patients at risk of developing immune-checkpoint pneumonitis.

Indexed as

Immune Checkpoint InhibitorsLungMachine LearningNeoplasmsPneumoniaTomography, X-Ray ComputedAgedFemaleHumansMaleMiddle AgedNeoplasm StagingRadiomicsRetrospective StudiesROC CurveImmune Checkpoint Inhibitorsimmune checkpoint inhibitorsimmune checkpoint pneumonitisimmune-related adverse eventsmachine learningradiomics

Identifiers

PMID40405704
PMCPMC12102562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.